Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Coronary Microvascular Dysfunction (CMD): early-phase trial registry
2 of 2 indexed Coronary Microvascular Dysfunction (CMD) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Coronary Microvascular Dysfunction (CMD): 2 US clinical trials tracked, 2 recruiting.
Coronary Microvascular Dysfunction (CMD) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Brigham and Women's Hospital, running 1 of these trials.
Enrollment posture brief
Registry condition coronary-microvascular-dysfunction-cmd
OPEN 2 | RECR 100% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Coronary Microvascular Dysfunction (CMD) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Coronary Microvascular Dysfunction (CMD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Coronary Microvascular Dysfunction (CMD) is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)
University of Virginia
NCT06600178
The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease
Brigham and Women's Hospital
NCT07222683
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Coronary Microvascular Dysfunction (CMD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Coronary Microvascular Dysfunction (CMD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Coronary Microvascular Dysfunction (CMD) page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Coronary Microvascular Dysfunction (CMD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Brigham and Women's Hospital sponsors the most Coronary Microvascular Dysfunction (CMD) trials on record, review their full trial history before evaluating a specific study. See Brigham and Women's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronary Microvascular Dysfunction (CMD) condition card totals 2 registered trials; most-linked intervention Brezavvy 20Mg Oral Tablet; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.